BriaCell Therapeutics Corp. (NASDAQ:BCTX) is the biggest gainer and trading with major rally in the pre-market session after the news this morning.
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor
- today provides an update on the overall survival (OS) data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell’s lead candidate Bria-IMT™ as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.) and Incyte’s retifanlimab (manufactured and provided under a corporate collaboration with Incyte Corporation).
- HLA-Typing: Cells with HLA (human leukocyte antigen) molecules on their surface determine and trigger the body’s immune response. BriaCell’s immunotherapy treatment appears most effective when the patient’s HLA-type matches with Bria-IMT™, allowing BriaCell to potentially identify patients most likely to respond. HLA-typing is a simple and widely available test.
- Tumor Grade: BriaCell has noted clinical benefit in its patients with grade I and grade II tumors, suggesting another subgroup of patients for whom BriaCell’s treatment would be most effective.
“Women with advanced breast cancer often are fighting a deadly disease that does not respond to currently-available treatments,” said Dr. Bill Williams, BriaCell’s President and CEO. “We are pleased to report that our immunotherapy regimen appears to offer clinical benefit for these patients in desperate need of new therapy options.”
Market Action
As of 8:54, BCTX stock soared $3.20 or 101% to $6.38. So far the stock has traded 9.39 million shares traded hands.
 Soars After Big News){kind=link}